Athenahealth sale ‘possible’ with activist investor taking 9.2% stake

Activist hedge fund manager Paul Singer of Elliott Management disclosed its 9.2 percent stake in Watertown, Massachusetts-based Athenahealth, sending the company’s stock price soaring.

While Elliott’s federal filing said it feels Athena is “significant undervalued,” according to Boston Business Journal, the ultimate goal may be to cost cuts or force a sale of the health IT company, as it has done in the past.

“While a sale of the company is possible, we note Elliott has pursued other paths to value in the past, and we believe the fund may push for a cost reduction program, given Athena’s revenue slow-down and high operating costs,” Leerink analysts said in a report.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.